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OBJECTIVE: To quantify the effect of treatment dura-
tion on life-long societal net value of glaucoma treatment
according to its treatment line in three European coun-
tries. METHODS: A Markov model was used to repro-
duce the average discounted (5%) cost and outcome of
glaucoma treatment over 30 years. Clinical states were
ﬁrst to fourth line treatment, no treatment, laser, surgery,
blindness and death. All patients started ﬁrst line, went
successively to the next line after failure. After each
failure (and always after the fourth line) patients could
have either laser or surgery followed by no treatment, or
a new ﬁrst line treatment. Transition probabilities and
resource utilisation (RU) came from of a cross-sectional
study with 5 years retrospective data collection for 
the glaucoma treatment, and from national statistics in
France. Expert interviews were conducted in Germany
and the Netherlands to collect RU. In-patient and outpa-
tient direct medical costs and indirect costs were esti-
mated from a societal point of view. Sensitivity analyses
and second order Monte-Carlo simulation were per-
formed. RESULTS: Life expectancy of this cohort (57
years old on average, 52% females) was 23.2 years.
Patients spent 9.8 years in ﬁrst line, 4.2 in second, 3.0 in
third, 2.2 in fourth, 3.6 without treatment, had 0.35
lasers and 1.17 surgeries. These ﬁgures became, respec-
tively, 11.77, 3.36, 2.41, 1.86, 3.47, 0.36 and 1.054 if
ﬁrst line treatment duration increased by 30% and 9.35,
5.52, 2.55, 1.97, 3.46, 0.35, 1.079 for a 30% 2nd line
duration increased. In France, €430 and €108 were saved
for a 30% ﬁrst and second line increased, respectively.
These ﬁgures were €241 and €30 in Germany and €257
and €55 in the Netherlands. Patients spent less time in
long-term institution. CONCLUSION: Increasing ﬁrst
line or second line glaucoma treatment duration is a cost
saving approach over life of a patient according to our
model.
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OBJECTIVE: To compare model estimates of the cost-
effectiveness of latanoprost and travoprost versus timolol.
METHODS: The probability of developing a visual ﬁeld
defect (VFD) was estimated using data from a double-
masked double-dummy Phase III multi-centre clinical trial
comparing travoprost 0.004%od, latanoprost 0.005%
od and timolol 0.5%bid, and the 2 discriminant func-
tions published by Stewart (1993). A Markov model was
constructed to estimate the cost and effectiveness (time to
disease progression) of patients treated over ﬁve years for
two states: those who do and those who do not develop
a VFD. Resource utilisation was estimated from a 5-year
retrospective patient chart analysis in France, from the
UK General Practitioner Data Base in the UK, and from
expert interviews in Germany. Both costs and outcomes
were discounted at a 5% rate. The economic perspective
was that of the Heath Care Sick Fund. RESULTS: The
average time to disease progression was estimated to be
2.81 years with timolol, 3.28 with latanoprost and 3.42
with travoprost. In France, over 5 years, a latanoprost
treated-patient is predicted to cost 277.6 more than a
timolol-treated patient while the ﬁgure for a travoprost-
treated patient is EUR 403.7. In Germany, these ﬁgures
were €858.60 and €714.80, for latanoprost and travo-
prost respectively. The corresponding amounts in the UK
were €288.9 and €251.1. In the UK and in Germany,
travoprost was predicted to be more effective and less
costly than latanoprost. Comparing the prostaglandin
analogues in France, travoprost’s incremental additional
5 year cost is modelled to be €951.4 per additional disease
free year. CONCLUSION: According to our model,
travoprost is a cost-effective alternative to timolol and
latanoprost.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of intraocular lens material (PMMA,
silicone, acrylic hydrophilic, and hydrophobic) implanted
during cataract surgery with reference to Yag-laser cap-
sulotomy and Yag-laser complications in four European
countries (France, Italy, Germany and Spain). Setting: A
retrospective review of 1525 patients (eyes), aged 50 to
80 years, operated with phaco-emulsiﬁcation for cataract
in 1996 or 1997 in 16 surgical centres (4 per country).
METHODS: The study was conducted using a cost-
effectiveness approach. Medical charts were reviewed to
collect retrospective information during the 3-year period
following cataract surgery in order to identify patients
who underwent YAG laser capsulotomy post-operatively.
Clinical data were combined with unit costs assessed by
experts for Yag laser capsulotomy and Yag complications.
A cost-effectiveness ratio (cost per patient without Yag
laser capsultomy intervention) was estimated in relation
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to each IOL material used in each of the 4 countries.
RESULTS: Ranking the materials in the countries shows
that hydrophobic acrylic is number one in all the coun-
tries except Germany where it was second. PMMA had
the best ratio in Germany, was second in Spain and only
third in Italy and France. Silicone was second in France
and ranked third in the other countries. Hydrophilic had
the worst ratio overall in all countries. CONCLUSIONS:
Cost effectiveness ratios of hydrophobic acrylic were
better than those of the other types of IOL materials used
in most countries. Sensitivity analyses were performed to
vary the base case analysis to demonstrate the economic
importance of the assumptions. In all cases, acrylic
hydrophobic IOL material was shown to be a cost-
effective option.
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OBJECTIVES: To assess resource utilization and direct
costs associated with managing glaucoma patients initi-
ated on medical therapy over a 2-year period in France
and Sweden. METHODS: A total of 267 adult patient
records (121 in France, 146 in Sweden) were randomly
selected from 4 sites per country based on a diagnosis of
primary open-angle glaucoma (POAG) or ocular hyper-
tension (OH). Patients had to have a minimum of 2-years
follow-up, beginning in December 1997, and started on
medical therapy at the time of study entry. Patients were
excluded based on ocular comorbidities, early glaucoma
surgical management, and prolonged hospitalization.
Records were reviewed for clinical and resource data
including intraocular pressure (IOP) measurements,
visual ﬁeld parameters, medical consultations, as well as
glaucoma medications, tests, and surgeries. Patients with
available clinical data were stratiﬁed according to sever-
ity. Resource data were assigned economic valuation to
determine direct costs from the third-party payer per-
spective. Multiple regression analyses were then per-
formed to identify the main cost drivers in treatment.
RESULTS: The total average annual direct cost of treat-
ing glaucoma was estimated at €467 patient for all
patients. In Sweden, the total annual direct cost was
higher than in France (€531 patient vs. €390 patient).
Glaucoma medication costs comprised 49% of total
direct cost in both countries. Results from the linear
regression analysis indicated that patients with the great-
est severity categories had drug costs that are 1.8–3.0
times higher, and total costs 3.6 times higher than for less
severe patients. Patients with higher baseline IOPs were
found to have higher average treatment costs. CON-
CLUSIONS: Glaucoma treatment costs in Europe are
particularly signiﬁcant for end-stage and higher baseline
IOPs patients. Treatment costs represent a substantial
proportion of direct costs. These ﬁndings suggest that
therapies targeted at efﬁcient IOP control slowing disease
progression will prove to be the most cost-efﬁcient.
EYE DISORDERS—Quality of Life Studies
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OBJECTIVE: Physicians need reliable, valid and sensitive
questionnaires to assess QoL related to glaucoma or
ocular hypertension. This abstract presents the psycho-
metric properties of the French version of the NEI-VFQ-
25. METHODS: This study was conducted with the
Sofres institute. Sending a mail survey to 20,000 house-
holds identiﬁed residents with glaucoma or ocular hyper-
tension. A random sample took part in a telephone
survey. Principal Component Analysis (PCA) and Multi-
trait analysis were performed to assess the construct
validity of the questionnaire. Internal consistency relia-
bility was assessed using Cronbach’s alpha and the
average inter-item correlation. Known-group validity was
assessed by comparing patients grouped by duration of
glaucoma, adjusted for age and gender. RESULTS: A total
of 173 patients suffering from a glaucoma or ocular
hypertension and taking treatment participated in the
survey. Twelve factors were retained by the PCA, together
explaining 84.54% of the total variance. Analysis of con-
vergent validity showed that all of the items in each scale
correlated above 0.40 with their own scale except for the
Driving scale. Success rate of the discriminant validity
ranged from 57.1% to 92.9% except for the Driving
scale, which was lower. Cronbach’s alpha coefﬁcients
were all above 0.70 excepted for the driving score. Par-
ticipants with glaucoma for less than 20 years consistently
had better Global, Near vision, Distant vision, Driving,
Social function and Peripheral vision scores than those
with 20+ years indicating better QoL. CONCLUSION:
Our results showed that the NEI-VFQ25 is a validated
instrument to measure vision-targeted QoL in French
populations with glaucoma.
